- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Teva telegraphs 61 job cuts amid plans to close 'underutilized' New Jersey plant | ||
| Di | Vanda eyes GLP-1 nausea indication with Nereus phase 3 win in hand | ||
| Di | UCB's Bimzelx leads pharmna's Q3 drug ad spend, but who will take the annual prize? | ||
| Di | Pfizer heads to FDA with phase 3 myeloma win for Elrexfio | ||
| Di | Novartis CEO unfazed by high-profile clinical failures, maintains long-term revenue goal | ||
| Di | WuXi AppTec bucks DOD uncertainty through Q3, lifting forecast for 2026 | ||
| Di | Eli Lilly fends off Novo's legal bid to block GLP-1 marketing claims | ||
| Di | Sun locks in first DTC spot for alopecia areata med Leqselvi | ||
| Di | Regeneron lands $270M in renewed US supply pact for approved Ebola med Inmazeb | ||
| Mo | Pfizer's Talzenna combo moves up treatment line with new FDA nod in prostate cancer | ||
| Mo | ESMO: In sac-TMT's first global phase 3 win, Merck sees 'pretty consistent' data with China | ||
| Mo | Novartis' Rhapsido touts solid efficacy with industry-best safety data in RMS phase 3 reveal | ||
| Mo | ESMO: Bristol Myers CMO touts '5 out of 5' positive phase 3 trials for bispecific ADC iza-bren | ||
| So | 'Infinite potential': Akeso CEO looks for more ivonescimab combos amid AstraZeneca investment, new phase 3 win | ||
| So | ESMO: AZ, Hutchmed's Orpathys combo shows post-Tagrisso power in MET-driven lung cancer | ||
| So | ESMO: Merck, Kelun's 'workhorse' ADC posts major tumor progression benefit in PD-L1-negative NSCLC | ||
| Sa | ESMO: Chasing Keytruda, AstraZeneca's Imfinzi pitches its own Padcev combos in bladder cancer | ||
| Sa | ESMO: Amgen's Imdelltra drives massive survival benefit in 'watershed moment' for small cell lung cancer | ||
| Sa | Bayer's Nubeqa scores phase 3 win in high-risk prostate cancer | ||
| Sa | The Oral GLP-1 Tracker: Foundayo, Wegovy pill take slight dip amid holiday week | ||
| 23.10. | Biopharma Companies Must Break the DMTA Linearity | ||
| 23.10. | Argenx confirmatory trial update for Vyvgart puts small dent in strong Q3 | ||
| 23.10. | Gilead to pay $45M as it settles Medicaid kickback allegations from Texas AG Paxton | ||
| 23.10. | GSK's double FDA win, Roche's $15B deal and the rise of point-of-care marketing | ||
| 23.10. | Fierce Pharma Asia-US Treasury homes in on China deals; Hengrui's secret sauce; Samsung Bio's strike developments |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.